European Society of Cardiology
Skip navigation links
Home
About the ESC
Membership
Communities
Congresses
Education
Guidelines & Surveys
Journals
Initiatives
Welcome to the European Society of Cardiology. Our mission: to reduce the burden of cardiovascular disease in Europe
 
Ruilope

About CVCT Meetings

Reports and Interviews

Incoming chair of the European Society of Cardiology’s Working Group on Pharmacology, Pr Luis Ruilope has attended CVCT Forum at least eight times. He has seen the conference develop since its early days and it remains a highlight on his meeting calendar.
Here, he explains why CVCT Forum is his preferred event for sparking imagination among colleagues, dynamic learning and generating new ideas and projects


"A quite complete picture "

“To me the advantage of CVCT Forum is that it is the only meeting in which you are updated with all the recently finished and ongoing trials,” he said. “Hot topics are debated and this makes quite a complete picture of cardiovascular disease in the sense of how it has to be treated. For people interested in cardiovascular disease CVCT Forum can easily update you on all the things that are relevant in two and a half days.”

Another reason Pr Ruilope keeps coming back to CVCT is for the networking  possibilities. “This meeting has a double advantage,” he explained. “You have the official sessions within the meeting at which senior and junior investigators can sit around one table and discuss. But you also have the opportunity for corridor discussions. These informal conversations improve your knowledge of what others are doing that may not be in the program.


"A stronger focus on the interaction "

“If you attend ESC you have the most complete information, of course, but that is a huge meeting. CVCT is specifically devoted to trials and those experts are more easily accessible than at a big meeting.”

But perhaps the most important benefit of attending CVCT Forum for Pr Ruilope is the way in which content is presented. “The trials that you hear about at CVCT may well be addressed in other meetings,” he remarked. “However, instead of just talking about the content and results of the trial, at CVCT presenters go much deeper into the process and caveats, with critical analysis at the conclusion of a trial on how the data was gathered. Often conferences provide only a few minutes at the end of the presentation for discussion because the speaker has supposedly explained the totality of the topic, leaving nothing open to doubt. At CVCT it is precisely those questions that are at the heart of the conference, with a stronger focus on the interaction than on the lecture.”

The stimulating, interactive session format is what encourages Pr Ruilope to return to CVCT Forum and he is pleased to see the next wave of investigators and other members of the medical trial community so engaged with the meeting. “Young investigators today require imagination,” he said. “The pharmaceutical industry requires imagination, too, not only for new drugs but also for new trials that profile those drugs. If we sit down for an hour I can give you countless new ideas for trials but perhaps not one of them will become a reality. CVCT brings the funding institutions – both government and industry – to the place where they can meet the trialists and prepare together for work ahead.”


A young clinical trialists Grant

The 2010 CVCT Forum is proud to announce the following grant specifically for young clinical trialists interested in learning more about the most up-to-date trials in cardiovascular disease. 

The Grant: one full scientific registration to attend CVCT 2010 in Paris (including congress materials, lunches and coffee breaks) as well as two nights’ hotel accommodation and a travel grant of up to 200 €.

Apply now for the new CVCT 2010 Young Clinical Trialists Grant


Past meeting reports & recordings